Advanced Maternal Age and the Risk of Major Congenital Anomalies by Goetzinger, Katherine R. et al.
Advanced Maternal Age and the Risk of Major
Congenital Anomalies
Katherine R. Goetzinger, MD, MSCI1 Anthony L. Shanks, MD2 Anthony O. Odibo, MD, MSCE3
George A. Macones, MD, MSCE4 Alison G. Cahill, MD, MSCI4
1Department of Obstetrics, Gynecology and Reproductive Sciences,
University of Maryland, Baltimore, Maryland
2Department of Obstetrics and Gynecology, Indiana University School
of Medicine, Indianapolis, Indiana
3Department of Obstetrics and Gynecology, University of South
Florida, Tampa, Florida
4Department of Obstetrics and Gynecology, Washington University,
St. Louis, Missouri
Am J Perinatol
Address for correspondence Katherine R. Goetzinger, MD, MSCI,
Department of Obstetrics, Gynecology and Reproductive Sciences,
University of Maryland School of Medicine, 22 South Greene Street,
Room N6W104F, Baltimore, MD 21201
(e-mail: kgoetzinger@fpi.umaryland.edu).
Over the past 20 years, there has been an increasing trend in the
number of pregnancies achieved by women of advancedmater-
nal age (AMA).1Thesewomenare at an increased riskofmultiple
pregnancy complications such as spontaneous abortion, pre-
eclampsia, gestational diabetes, fetal growth restriction, and
stillbirth.2–6 In addition, AMA is a well-established risk factor
for chromosomal abnormalities, such as trisomy 21, due to
errors in meiotic nondisjunction with advancing oocyte age.
Despite these known pregnancy risks, there exists limited data
evaluating the relationship between being AMA and the inci-
dence of congenital anomalies in the absence of aneuploidy.
Prior studies on this topic have generated conﬂicting
results.2,7–12 In a large prospective cohort study, Hollier et
al demonstrated an additional 1% age-related risk of non-
chromosomal abnormalities in women age 35 or older.7
Conversely, Baird et al found no association between the
incidence of congenital malformations and advancing mater-
nal age.8 In fact, more recent studies suggest that young
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Abstract Objective This study aims to determine if advancedmaternal age (AMA) is a risk factor
for major congenital anomalies, in the absence of aneuploidy.
Study Design Retrospective cohort study of all patients with a singleton gestation
presenting for second trimester anatomic survey over a 19-year study period. Aneuploid
fetuses were excluded. Study groups were deﬁned by maternal age  34 and  35
years. The primary outcome was the presence of one or more major anomalies
diagnosed at the second trimester ultrasound. Univariable and multivariable logistic
regression analyses were used to estimate the risk of major anomalies in AMA patients.
Results Of 76,156 euploid fetuses, 2.4% (n ¼ 1,804) were diagnosed with a major
anomaly. There was a signiﬁcant decrease in the incidence of major fetal anomalies with
increasing maternal age until the threshold of age 35 (p < 0.001). Being AMA was
signiﬁcantly associated with an overall decreased risk for major fetal anomalies
(adjusted odds ratio: 0.59, 95% conﬁdence interval: 0.52–0.66). The subgroup analysis
demonstrated similar results for women  40 years of age.
Conclusion AMA is associated with an overall decreased risk for major anomalies.
These ﬁndings may suggest that the “all or nothing” phenomenon plays a more robust
role in embryonic development with advancing oocyte age, with anatomically normal
fetuses being more likely to survive.
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maternal age actually may be a stronger risk factor for certain
congenital anomalies compared with advanced age.12–14
Limitations of many of these studies include their reliance
on birth certiﬁcate data, which is often incomplete and
subject to ascertainment bias. Furthermore, the majority of
available studies have been unable to capture information on
stillbirths and terminations, thereby likely missing a signiﬁ-
cant proportion of anomalous fetuses. Finally, existing studies
largely have been unable to account for the multiple con-
founders that may independently increase the risk for con-
genital anomalies.
Given this limited and conﬂicting data, the objective of this
study was to estimate the risk of major congenital anomalies
in women of advanced maternal age in the absence of
aneuploidy using a large ultrasound and perinatal database.
This information will be useful in counseling women about
their risk of having a structurally normal fetus, especially in
the setting of normal aneuploidy screening.
Materials and Methods
This was a retrospective cohort study of consecutive patients
with a singleton gestation presenting to the Division of Ultra-
sound and Genetics, Washington University in St. Louis for
second-trimester anatomic survey from 1990 to 2009. Institu-
tional review board approval from our institutionwas obtained.
All anatomic surveys performed between 16 and 24 weeks
gestation were included. If all sonographic views could not be
completedduring the initial examination, patientswere asked to
return in 2 to 4 weeks’ time for completion of the anatomic
survey. Multiple gestations and pregnancies with chromosomal
abnormalitieswere excluded. Chromosomal abnormalitieswere
identiﬁed through prenatal diagnosis or postnatal testing, when
examination ﬁndings were suspicious. Maternal demographic
information, obstetrical history, andmedical history are routine-
lyobtained through patient questionnaire at each encounter and
entered into a comprehensive database. All suspected fetal
anomalies and sonographic markers of aneuploidy are also
entered into this database at the time of the examination.
Ultrasoundexaminations areperformedbydedicatedobstetrical
sonographers and are interpreted by maternal–fetal medicine
specialists. Pregnancy and neonatal outcomes are prospectively
collected by a dedicated nurse outcome coordinator. All sono-
graphically suspected fetal anomalies are conﬁrmed after birth.
In addition, anomalies diagnosed after birth are also collected
and entered into the databaseby thenurse outcome coordinator.
Neonatal information is obtained by medical record abstraction
as well as questionnaire or phone call to the patient or referring
obstetric provider.
Study groups were deﬁned by maternal age  34 years and
maternal age  35 years at the time of delivery.15 The primary
outcome of the study was the presence of one or more major
anomalies diagnosed at the time of second trimester ultrasound.
This outcomewas chosen to capture all anomalous pregnancies,
including those that may result in stillbirth or termination. An
anomaly was deﬁned as a defect in the structure of an organ
which resulted from a speciﬁc primary abnormality of organo-
genesis.16 Examples ofmajor anomalies include congenital heart
defects, neural tube defects, gastroschisis, and omphalocele.
Markers of aneuploidy, such as thickened nuchal fold or
absent/hypoplastic nasal bone, were not considered to be major
congenital anomalies. Secondary outcomes included the distri-
bution of individual major congenital anomalies by organ
system, including central nervous system (CNS), cardiac, renal,
thoracic, head and neck, musculoskeletal, gastrointestinal, and
abdominal wall defects.
Baseline maternal characteristics as well as the incidence
of the primary and secondary outcomes were compared
between the study groups using chi-square and Fisher exact
tests for categorical variables and Student t-test for continu-
ous variables. Normality of distribution was assessed using
the Kolmogorov–Smirnov test. The distribution of anomaly
type by organ system was also compared between the study
groups. A Cochran–Armitage test for trend was used to
evaluate for any signiﬁcant pattern in the incidence of major
fetal malformations across maternal age categories. Univari-
able analysis was used to estimate the relative risks (RR) and
95% conﬁdence intervals (CIs) of the association between the
AMA and major congenital malformations. Multivariable
logistic regression analysis then was used to estimate the
adjusted odds ratio (aOR) for the primary and secondary
outcomes, controlling for confounders identiﬁed both histor-
ically and through univariable analysis. Separate logistic
regression models were run for each organ system, and
nonsigniﬁcant variables were removed in a backward step-
wise fashion. A subgroup analysis was also performed com-
paring the risk of major congenital anomalies in women
age  40 years and women  39 years. The p values < 0.05
were considered statistically signiﬁcant. All statistical analy-
sis was performed using STATA 12.0 special edition software
(StataCorp, College Station, TX).
Results
A total of 76,453 patients with singleton gestations were
included in our perinatal database over the study period. After
excluding 297 (0.4%) patients with fetal chromosomal abnor-
malities, 76,156 patients comprised our ﬁnal study cohort. Of
these patients, 20,803 (27.3%) were AMA. On average, patients
who were AMA were of higher gravidity and parity and had a
lower bodymass index (BMI) comparedwith patientswhowere
not AMA. Patients who were AMA also were more likely to be
Caucasian, report a history of alcohol use during pregnancy and
have a history of chronic hypertension and/or diabetes (both
preexisting and gestational) (►Table 1). Finally, patients who
were AMAwere signiﬁcantly more likely to present at an earlier
gestational age for second trimester anatomic survey compared
with patients  34 years old (18.7  1.6 weeks vs. 19.4  1.7
weeks; p < 0.001).
The overall incidence of major fetal anomalies in our cohort
was 2.4% (n ¼ 1,804). There was a statistically signiﬁcant
decrease in the incidence of all major congenital anomalies
with increasing maternal age until the threshold of age 35
(p < 0.001). This incidence ranged from 3.2% in women < 20
years old to 1.7% in women > 35 years old (►Fig. 1). ►Fig. 2
demonstrates the distribution of the major anomalies by organ
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system compared between the study groups. CNS, cardiac and
renal anomalies were the most common organ system malfor-
mations in both the AMA patients and patients  34 years old.
Abdominal wall defects (both gastroschisis and omphalocele)
were observed more frequently in patients  34 years old;
whereas, head and neck malformations were observed more
frequently in AMA patients. The other anomaly distributions
were similar between the study groups.
Overall, AMA was signiﬁcantly associated with a 40%
reduction in the risk of having one or more major fetal
congenital anomalies compared with women  34 years
old, after controlling for race, diabetes, and alcohol use during
pregnancy (1.7% vs. 2.6%; aOR: 0.59, 95% CI: 0.52–0.66). On
evaluation ofmajor anomalies byorgan system, AMApatients
were also less likely to be diagnosed with a fetal CNS, renal,
thoracic or abdominal wall defect after controlling for con-
founders. The incidence of cardiac, head/neck, gastrointesti-
nal, and skeletal anomalies was similar between the study
groups (►Table 2). Given the small absolute number of
anomalies in the organ system categories of head/neck,
gastrointestinal, andmusculoskeletal, adjusted analysis could
not reliably be performed.
Similar results were obtained in a subgroup analysis of
women  40 years old (n ¼ 4,065). Women who were  40
were also at a signiﬁcantly decreased risk of having any major
fetal anomaly (aOR: 0.70, 95% CI: 0.54–0.90) after controlling for
alcohol use, diabetes, race, and BMI. In addition, women who
were  40 were also less likely to be diagnosed with a fetal
CNS (aOR: 0.49, 95% CI: 0.29–0.84) or renal (RR: 0.16, 95% CI:
0.04–0.64) anomaly compared with women  39 years old.
Similar to the primary analysis, the incidence of cardiac defects
did not differ between the two study groups (►Table 3).
To account for the 19 year study period and associated
improvements in ultrasound diagnosis and technology over
time, we divided the study period into 5-year quartiles and
evaluated the incidence ofmajor anomalies diagnosed in each
quartile. Each quartile demonstrated a consistent incidence of
anomalies of approximately 2%, indicating the stability of
sonographic diagnosis over time at our institution.
Comment
Our study demonstrates that AMA is associated with an
overall decreased risk for major congenital malformations
in the absence of aneuploidy. This decrease in risk appears to
be primarily driven by a decreased incidence of CNS, renal
and abdominal wall defects, and contrasted by a similar
incidence of cardiac defects. In addition, comparable results
were observed using varying thresholds to deﬁne AMA, thus
strengthening the validity of our ﬁndings.
The limited number of studies that do exist on this topic
have generated conﬂicting results. In 2000, Hollier et al
published a large prospective cohort study of 102,728 single-
ton pregnancies, both liveborn and stillborn, delivered over a
7-year period at a tertiary care center. When evaluating the
Fig. 1 Incidence of major congenital anomalies by maternal age. The
x-axis represents maternal age in 5-year age increments. The y-axis
represents the incidence of major congenital anomalies in absolute
percentages. The p value obtained from Cochran–Armitage test for
trend.
Fig. 2 Distribution of anomalies by organ system in both the AMA
group and age  34 referent group. AMA, advanced maternal age.
Table 1 Maternal demographics and pregnancy characteristics
compared between patients  35 y (AMA) and  34 y
Variable AMA
n ¼ 20,803
Age  34
n ¼ 55,353
p Value
Mean Maternal
Age (y)a
37.6  2.3 26.9  4.8 < 0.001
Mean graviditya 3.3  1.8 2.4  1.5 < 0.001
Mean paritya 1.4  1.3 0.9  1.1 < 0.001
Mean BMI (kg/m2)a 26.8  6.4 27.1  6.7 < 0.001
Caucasian race 70.2% 54.8% < 0.001
African American
race
12.6% 29.9% < 0.001
Tobacco exposure 11.5% 11.9% 0.13
Alcohol exposure 26.8% 14.7% < 0.001
Maternal chronic
hypertension
3.9% 1.9% < 0.001
Maternal diabetes 8.3% 5.3% < 0.001
Preeclampsia 7.0% 8.4% < 0.001
Abbreviations: AMA, advanced maternal age; BMI, body mass index.
aData reported as mean  standard deviation.
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Table 2 Association between AMA  35 y and major congenital anomalies by organ system
Variable AMA
n ¼ 20,803
Age  34
n ¼ 55,353
RR
(95% CI)
aOR
(95% CI)
p Value
One or more major anomalies
(n ¼ 1,804)
1.7% 2.6% 0.66
(0.59–0.74)
0.59a
(0.52–0.66)
< 0.001
CNS
(n ¼ 496)
0.4% 0.7% 0.55
(0.43–0.6)
0.49a
(0.38–0.62)
< 0.001
Renal
(n ¼ 226)
0.2% 0.3% 0.66
(0.48–0.92)
0.58b
(0.41–0.81)
0.002
Abdominal wall
(n ¼ 189)
0.1% 0.3% 0.21
(0.12–0.37)
0.23c
(0.13–0.40)
< 0.001
Cardiac
(n ¼ 302)
0.4% 0.4% 0.92
(0.72–1.20)
0.89d
(0.68–1.18)
0.56
Thoracic
(n ¼ 103)
0.09% 0.15% 0.60
(0.36–0.98)
0.56e
(0.34–0.93)
0.04
Head/neck
(n ¼ 122)
0.15% 0.16% 0.91
(0.60–1.36)
– 0.64
Gastrointestinal
(n ¼ 39)
0.03% 0.06% 0.58
(0.26–1.32)
– 0.19
Musculoskeletal
(n ¼ 131)
0.13% 0.19% 0.91
(0.60–1.36)
– 0.64
Abbreviations: AMA, advanced maternal age; aOR, adjusted odds ratio; CI, conﬁdence interval; CNS, central nervous system; RR, relative risk.
aAdjusted for alcohol use, diabetes, and African American race.
bAdjusted for diabetes and African American race.
cAdjusted for tobacco use, parity, and African American race.
dAdjusted for diabetes, African American race, and body mass index.
eAdjusted for African American race.
Table 3 Subgroup analysis of the association between AMA  40 y and major congenital anomalies by organ system
Variable AMA  40
n ¼ 4,065
Age  39
n ¼ 72,091
RR
(95% CI)
aOR
(95% CI)
p Value
One or more major anomalies
(n ¼ 1,804)
1.8% 2.4% 0.73
(0.58–0.93)
0.70a
(0.54–0.90)
0.02
CNS
(n ¼ 496)
0.3% 0.7% 0.51
(0.30–0.67)
0.49b
(0.29–0.84)
0.01
Renal
(n ¼ 226)
0.05% 0.31% 0.16
(0.04–0.64)
– 0.003
Abdominal wall
(n ¼ 189)
0.12% 0.26% 0.48
(0.20–1.17)
– 0.09
Cardiac
(n ¼ 302)
0.6% 0.4% 1.67
(1.12–2.49)
1.55c
(1.00–2.42)
0.05
Thoracic
(n ¼ 103)
0.17% 0.13% 1.29
(0.60–2.78)
– 0.51
Head/neck
(n ¼ 122)
0.12% 0.16% 0.76
(0.30–1.85)
– 0.54
Gastrointestinal
(n ¼ 39)
0.05% 0.05% 0.96
(0.23–3.97)
– 0.95
Musculoskeletal
(n ¼ 131)
0.12% 0.17% 0.70
(0.29–1.72)
– 0.44
Abbreviations: AMA, advanced maternal age; aOR, adjusted odds ratio; CI, conﬁdence interval; CNS, central nervous system; RR, relative risk.
aAdjusted for alcohol use, African American race, diabetes, and body mass index.
bAdjusted for diabetes, alcohol use, and African American race.
cAdjusted for diabetes, African American race, and body mass index.
American Journal of Perinatology
AMA and the Risk of Major Congenital Anomalies Goetzinger et al.
risk of major anomalies by 5-year age increments, the authors
demonstrated that women older than age 25 had a signiﬁ-
cantly and progressively greater risk of having a fetus with a
nonchromosomal malformation compared with the reference
group of women ages 20 to 24 years. Speciﬁcally, women older
than 25 years had an increased risk for cardiac defects,
clubfoot, and diaphragmatic hernia, with this risk most pro-
nounced in women  age 40.7 Despite the large number of
patients included in this study, the absolute number of indi-
vidual anomalies was low, resulting in wide CIs around the
estimated ORs. Similar results were obtained in a secondary
analysis of the FASTER (ﬁrst and second trimester evaluation of
risk) trial in which an increased risk of congenital anomalies
was observed in women aged 35 to 39 (aOR: 1.4, 95% CI: 1.1–
1.8) and women  40 (aOR: 1.7, 95% CI: 1.2–2.4). That study,
however, did not differentiate between congenital anomalies
associated with aneuploidy and isolated anomalies.2
In contrast, Baird et al performed a population-based analysis
using birth certiﬁcate data from 576,815 consecutive livebirths
to evaluate the effect of maternal age on the incidence of
nonchromosomal congenital anomalies. These authors demon-
strated no increase in congenital anomalies with advancing
maternal age.8 Furthermore, a Swedish birth registry study of
nearly 574,000 livebirths and stillbirths reported no increase in
the incidence of fetal cardiac defects with advancing maternal
age after excluding chromosomal abnormalities, consistent with
results from our study.17 Also consistent with our ﬁndings,
Materna-Kiryluk et al demonstrated a decreased risk for neural
tube defects with advancing maternal age.9
Multiple biological mechanisms have been proposed to
support both an increased and decreased risk for major congen-
ital anomalies with advancing maternal age. Mechanisms favor-
ing an increased risk include the increased incidence of
aneuploidy with advancing age, accumulation of environmental
exposures over time, and the increasing risk of medical comor-
bidities, such as diabetes, over the course of childbearing years.
Conversely, increasing prenatal vitamin use, decreasing sub-
stance abuse, and earlier prenatal care have been observed in
women of advancedmaternal age andmay explain the potential
decreased risk of congenital anomalies in these women. In
addition to these mechanisms, we propose a novel hypothesis
suggesting that the “all or nothing” phenomenon, a concept in
which early embryonic exposure before organogenesis either
results in embryonic death or no adverse outcome, may play a
more robust role in development with advancing oocyte age,
with anatomically normal fetuses being more likely to survive.
Future research to test this hypothesis invitromaybewarranted.
The strengths of our study include our large cohort estab-
lished by our robust ultrasound and perinatal database which is
maintained by a dedicated nurse outcome coordinator. Given
this expansive database, we were able to perform a rigorous
epidemiologic evaluation, capturing maternal characteristics,
ultrasound ﬁndings, and pregnancy comorbidities and allowing
for adjusted analysis to control for potential confounders which
may independently be associated with an increased risk for
congenital anomalies. Despite these large numbers,we stillwere
unable to evaluate individual congenital anomalies given their
overall rarity; however, we were able to evaluate anomalies by
organ system. Most importantly, by selecting our primary
outcome as the diagnosis of major fetal anomalies at the time
of the second trimester anatomic survey, we not only captured
live birth data, but also data for impending stillbirths and
terminations, which anecdotally are more likely to be anoma-
lous. Using our well-established follow-up system for pregnancy
and neonatal outcome extraction, sonographically suspected
major anomalies were able to be conﬁrmed in the postnatal
period. In addition, data on anomalies not detected by ultra-
sound could also be collected.
Our study is not without limitations, including its retro-
spective designwith its potential for misclassiﬁcation bias and
the effect of unknownconfounders; however, thenatureof this
research does not allow for the gold standard randomized
controlled trial design. In addition, our perinatal database
neither captures information on paternal age, which has
been associatedwith an increased risk for autosomaldominant
disorders and their associated anomalies, nor information on
the effect of assisted reproductive technology and donor
oocytes. Although our study was able to exclude chromosomal
abnormalities based on standard karyotype results, we were
unable to account for chromosomal deletion/duplication ab-
normalities assessed by chromosomal microarray analysis, as
this is a relatively new technology to be incorporated into our
practice. Finally, our population primarily represents a high-
risk referral population; however, the proportion of AMA
patients evaluated at our center is comparable to the national
average. Furthermore, a high-risk referral population would
likely have a higher incidence of fetal anomalies, thereby
biasing our results in the opposite direction, producing an
underestimation of the true association found.
In conclusion, AMA is associated with an overall decreased
risk for major congenital malformations in the absence of
aneuploidy, speciﬁcally driven by a decrease in CNS, renal,
and abdominalwall defects. In the era of noninvasive prenatal
testing, women are being informed of their aneuploidy risk as
early as 10weeks gestation,months before the time of routine
second-trimester anatomic survey. Findings from our study
may be used to provide reassurance to these patients during
this time of anticipation and may also be incorporated into
patient counseling as more women are considering pregnan-
cy at advancing maternal ages.
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